About: COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies
Creator	Zheng, Ming-Hua Yan, Byrne, Christopher Liu, Wen-Yue Poucke, Sven Rios, Rafael Targher, Giovanni Gong, Feng Zheng, Qin-Qin
topic	covid:fc75dda7d2ffa3d8ba1c1fca9256091e6615b746#this
Source	Medline; PMC; WHO
abstract	The outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has attracted increasing worldwide attention. Cases of liver damage or dysfunction (mainly characterized by moderately elevated serum aspartate aminotransferase levels) have been reported among patients with COVID-19. However, it is currently uncertain whether the COVID-19-related liver damage/dysfunction is due mainly to the viral infection per se or other coexisting conditions, such as the use of potentially hepatotoxic drugs and the coexistence of systemic inflammatory response, respiratory distress syndrome-induced hypoxia, and multiple organ dysfunction. Based on the current evidence from case reports and case series, this review article focuses on the demographic and clinical characteristics, potential mechanisms, and treatment options for COVID-19-related liver dysfunction. This review also describes the geographical and demographic distribution of COVID-19-related liver dysfunction, as well as possible underlying mechanisms linking COVID-19 to liver dysfunction, in order to facilitate future drug development, prevention, and control measures for COVID-19.
has issue date	2020-03-30(xsd:dateTime)
bibo:doi	10.14218/jcth.2020.00018
bibo:pmid	32274342
has license	cc-by-nc
sha1sum (hex)	fc75dda7d2ffa3d8ba1c1fca9256091e6615b746
schema:url	https://doi.org/10.14218/jcth.2020.00018
resource representing a document's title	COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies
has PubMed Central identifier	PMC7132016
has PubMed identifier	32274342
schema:publication	J Clin Transl Hepatol
resource representing a document's body	covid:fc75dda7d2ffa3d8ba1c1fca9256091e6615b746#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/fc75dda7d2ffa3d8ba1c1fca9256091e6615b746
is schema:about of	named entity 'conditions' named entity 'caused' named entity 'Liver' named entity 'UNCERTAIN' named entity 'ORGAN' named entity 'liver' named entity 'hepatotoxic' named entity 'smooth muscle cells' named entity 'liver function tests' named entity 'SARS-CoV-2' named entity 'antiviral treatment' named entity 'attracted' named entity 'However' named entity 'hepatotoxic' named entity 'hypoxia' named entity 'aspartate aminotransferase' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'case series' named entity 'serum' named entity 'COVID-19.' named entity 'coronavirus disease 2019' named entity 'dysfunction' named entity 'GM-CSF' named entity 'ACE-inhibitors' named entity 'alveolar epithelial cells' named entity 'liver dysfunction' named entity 'bile duct' named entity 'AST' named entity 'Wuhan' named entity 'virus' named entity 'infection' named entity 'IL-6' named entity 'lipid' named entity 'COVID' named entity 'epithelial cell' named entity 'infection' named entity 'liver disease' named entity 'case series' named entity 'lung' named entity 'angiotensin-II' named entity 'epidemic' named entity 'vaccines' named entity 'lopinavir' named entity 'Middle East respiratory syndrome coronavirus' named entity 'MHZ' named entity 'Wuhan' named entity 'COVID' named entity 'liver damage' named entity 'acetaminophen' named entity 'hypoxia' named entity 'liver dysfunction' named entity 'serum' named entity 'TLRs' named entity 'binding sites' named entity 'organ' named entity 'SARS-CoV-2' named entity 'N-terminal' named entity 'epidemic' named entity 'multiple organ dysfunction' named entity 'oral mucosa' named entity 'COVID' named entity 'liver dysfunction' named entity 'SARS-CoV-2' named entity 'liver dysfunction' named entity 'COVID' named entity 'vascular endothelial cells' named entity 'serum' named entity 'Glycyrrhizin' named entity 'infection' named entity 'lymphocytes' named entity 'apoptosis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software